RU2015119999A - Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака - Google Patents
Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака Download PDFInfo
- Publication number
- RU2015119999A RU2015119999A RU2015119999A RU2015119999A RU2015119999A RU 2015119999 A RU2015119999 A RU 2015119999A RU 2015119999 A RU2015119999 A RU 2015119999A RU 2015119999 A RU2015119999 A RU 2015119999A RU 2015119999 A RU2015119999 A RU 2015119999A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- aryl
- compound according
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims 18
- 238000011282 treatment Methods 0.000 title claims 15
- 239000003814 drug Substances 0.000 title claims 10
- 229940079593 drug Drugs 0.000 title claims 5
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 150000004712 monophosphates Chemical class 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000002718 pyrimidine nucleoside Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 99
- 150000001875 compounds Chemical class 0.000 claims abstract 68
- 125000003118 aryl group Chemical group 0.000 claims abstract 38
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 37
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 33
- 229910052799 carbon Inorganic materials 0.000 claims abstract 32
- 125000001424 substituent group Chemical group 0.000 claims abstract 29
- -1 cycloheteroalkyl Chemical group 0.000 claims abstract 26
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 25
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 25
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 21
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract 19
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 17
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 15
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 13
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 10
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract 10
- 150000002367 halogens Chemical class 0.000 claims abstract 10
- 125000005842 heteroatom Chemical group 0.000 claims abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 5
- 239000001177 diphosphate Substances 0.000 claims abstract 5
- 235000011180 diphosphates Nutrition 0.000 claims abstract 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000001226 triphosphate Substances 0.000 claims abstract 4
- 235000011178 triphosphate Nutrition 0.000 claims abstract 4
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 229940002612 prodrug Drugs 0.000 claims abstract 2
- 239000000651 prodrug Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 30
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 29
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 22
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 21
- 208000031886 HIV Infections Diseases 0.000 claims 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 12
- 241000700605 Viruses Species 0.000 claims 12
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 11
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 239000003937 drug carrier Substances 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 241001263478 Norovirus Species 0.000 claims 9
- 230000004071 biological effect Effects 0.000 claims 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 8
- 229910052794 bromium Inorganic materials 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 229910052740 iodine Inorganic materials 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 241000710781 Flaviviridae Species 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 241000725619 Dengue virus Species 0.000 claims 5
- 241000700721 Hepatitis B virus Species 0.000 claims 5
- 201000006449 West Nile encephalitis Diseases 0.000 claims 5
- 206010057293 West Nile viral infection Diseases 0.000 claims 5
- 241000710772 Yellow fever virus Species 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 229940051021 yellow-fever virus Drugs 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 3
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 229910052711 selenium Inorganic materials 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 claims 2
- 208000004576 Flaviviridae Infections Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000006302 indol-3-yl methyl group Chemical group [H]N1C([H])=C(C2=C([H])C([H])=C([H])C([H])=C12)C([H])([H])* 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 2
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 241000369757 Sapovirus Species 0.000 claims 1
- 150000001337 aliphatic alkines Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- JLXCKKKWUBELSL-UHFFFAOYSA-N diphosphono hydrogen phosphate;pyrimidine Chemical class C1=CN=CN=C1.OP(O)(=O)OP(O)(=O)OP(O)(O)=O JLXCKKKWUBELSL-UHFFFAOYSA-N 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719696P | 2012-10-29 | 2012-10-29 | |
| US61/719,696 | 2012-10-29 | ||
| US201361763534P | 2013-02-12 | 2013-02-12 | |
| US61/763,534 | 2013-02-12 | ||
| PCT/US2013/067309 WO2014070771A1 (en) | 2012-10-29 | 2013-10-29 | Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015119999A true RU2015119999A (ru) | 2016-12-20 |
Family
ID=50627997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015119999A RU2015119999A (ru) | 2012-10-29 | 2013-10-29 | Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9809616B2 (https=) |
| EP (1) | EP2912050A4 (https=) |
| JP (1) | JP2015535261A (https=) |
| KR (1) | KR20150090894A (https=) |
| CN (1) | CN104884462A (https=) |
| BR (1) | BR112015009636A8 (https=) |
| CA (1) | CA2889717A1 (https=) |
| HK (1) | HK1214270A1 (https=) |
| MX (1) | MX2015005500A (https=) |
| RU (1) | RU2015119999A (https=) |
| WO (1) | WO2014070771A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791523C1 (ru) * | 2022-12-08 | 2023-03-09 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-О-(3-фенилпропионил)-N4-гидроксицитидин и его применение |
| WO2024123207A1 (ru) * | 2022-12-08 | 2024-06-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение |
| WO2024123206A1 (ru) * | 2022-12-08 | 2024-06-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| EP3055319A4 (en) | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| US9828409B2 (en) * | 2014-03-19 | 2017-11-28 | Minghong Zhong | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides |
| MX381291B (es) * | 2014-09-26 | 2025-03-12 | Riboscience Llc | Derivados de nucleósidos sustituidos con 4'-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial. |
| SG10202013032YA (en) | 2014-12-15 | 2021-02-25 | Univ Emory | Phosphoramidates for the treatment of hepatitis b virus |
| DK3236972T3 (en) * | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2016178876A2 (en) * | 2015-05-01 | 2016-11-10 | Cocrystal Pharma, Inc. | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| WO2017156380A1 (en) * | 2016-03-10 | 2017-09-14 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US11963972B2 (en) | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
| BR112018076913A2 (pt) | 2016-06-24 | 2019-04-02 | Emory University | fosforamidatos para o tratamento do vírus da hepatite b |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| DK3512863T3 (da) | 2016-09-07 | 2022-03-07 | Atea Pharmaceuticals Inc | 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus |
| CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| JP6917078B2 (ja) * | 2017-03-10 | 2021-08-11 | レイクウッド アメディックス、インコーポレイテッド | 抗菌化合物、組成物、及びそれらの使用 |
| US12030908B2 (en) | 2017-03-10 | 2024-07-09 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| MX2020011912A (es) * | 2018-05-09 | 2021-01-29 | Cocrystal Pharma Inc | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). |
| CN110075291B (zh) * | 2019-02-01 | 2023-01-06 | 广州中医药大学(广州中医药研究院) | 一种单磷酸类酯A缀合Tn抗肿瘤疫苗及其应用 |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| EA202193251A1 (ru) | 2019-06-05 | 2022-03-10 | Эмори Юниверсити | Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2022008025A1 (en) * | 2020-07-05 | 2022-01-13 | Since & Technology Development Fund Authority | 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto |
| JP7774836B2 (ja) * | 2021-01-29 | 2025-11-25 | 国立大学法人東海国立大学機構 | プロドラッグ化合物 |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| US20240239832A1 (en) * | 2021-05-06 | 2024-07-18 | Council Of Scientific And Industrial Research | A process for the preparation of n4-hydroxycytidine and its derivatives |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
| CN113321694A (zh) * | 2021-06-22 | 2021-08-31 | 药康众拓(江苏)医药科技有限公司 | N4-羟基胞苷衍生物及其制备方法和用途 |
| CN113278041B (zh) * | 2021-07-16 | 2021-10-19 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用 |
| CN115960148B (zh) * | 2021-08-27 | 2023-12-12 | 南京知和医药科技有限公司 | 一种新型的胞苷衍生物及其药物组合物和用途 |
| CN113735928A (zh) * | 2021-10-21 | 2021-12-03 | 药康众拓(江苏)医药科技有限公司 | 一种n4-羟基胞苷衍生物及其制备方法和用途 |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| TW202400134A (zh) | 2022-03-15 | 2024-01-01 | 美商羅米醫療公司 | 用於治療疾病之化合物及方法 |
| CN114437159B (zh) * | 2022-04-11 | 2022-06-28 | 佛山市晨康生物科技有限公司 | 一种环状碳酸酯核苷类化合物及其应用 |
| CN117285566A (zh) * | 2022-06-24 | 2023-12-26 | 润佳（苏州）医药科技有限公司 | 一种膦酸酯类化合物及其医药用途 |
| CN117586330A (zh) * | 2022-08-12 | 2024-02-23 | 南京知和医药科技有限公司 | 一种新型核苷衍生物及其药物组合物和用途 |
| WO2024249234A1 (en) * | 2023-05-26 | 2024-12-05 | Altesa BioSciences, Inc. | Method of treating hepatitis c virus in patients |
| CN121889150A (zh) * | 2023-07-27 | 2026-04-17 | 默沙东有限责任公司 | 小分子抗病毒剂的固体剂型及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0355031A3 (de) | 1988-08-17 | 1990-12-27 | MATTHES, Eckart, Dr. | Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
| CN1081477A (zh) | 1992-07-23 | 1994-02-02 | 康那香企业股份有限公司 | 纸纤不织布高分子吸水层的制造方法 |
| JPH07155184A (ja) | 1993-12-08 | 1995-06-20 | Ajinomoto Co Inc | 発酵法によるｌ−リジンの製造法 |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| KR20090089922A (ko) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| US7049303B2 (en) * | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
| KR20040094692A (ko) * | 2002-02-14 | 2004-11-10 | 파마셋, 리미티드 | 변형된 불소화 뉴클레오사이드 유사체 |
| AU2003232071A1 (en) * | 2002-05-06 | 2003-11-17 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| AU2003279797B2 (en) * | 2002-09-30 | 2009-10-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| WO2004037159A2 (en) | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| US7799908B2 (en) * | 2003-01-15 | 2010-09-21 | Valeant Pharmaceuticals North America | Synthesis and use of 2′-substituted-N6 -modified nucleosides |
| US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
| WO2005020885A2 (en) * | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| CN1315863C (zh) * | 2003-12-12 | 2007-05-16 | 河南省科学院质量检验与分析测试研究中心 | β－L－2'－脱氧－核苷衍生物、其合成方法及其药物用途 |
| DE102004051804A1 (de) * | 2004-10-21 | 2006-04-27 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen |
| JP2012517443A (ja) * | 2009-02-06 | 2012-08-02 | アールエフエス ファーマ，エルエルシー | 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ |
| CN102351931B (zh) * | 2010-09-07 | 2014-01-22 | 河南省科学院高新技术研究中心 | 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用 |
| CN102558263A (zh) * | 2010-12-28 | 2012-07-11 | 上海瑞广生化科技开发有限公司 | 去氧氟尿苷类衍生物,其制备方法及其制药用途 |
-
2013
- 2013-10-29 BR BR112015009636A patent/BR112015009636A8/pt not_active Application Discontinuation
- 2013-10-29 JP JP2015539919A patent/JP2015535261A/ja active Pending
- 2013-10-29 WO PCT/US2013/067309 patent/WO2014070771A1/en not_active Ceased
- 2013-10-29 CA CA2889717A patent/CA2889717A1/en not_active Abandoned
- 2013-10-29 RU RU2015119999A patent/RU2015119999A/ru not_active Application Discontinuation
- 2013-10-29 MX MX2015005500A patent/MX2015005500A/es unknown
- 2013-10-29 KR KR1020157014128A patent/KR20150090894A/ko not_active Ceased
- 2013-10-29 US US14/066,461 patent/US9809616B2/en active Active
- 2013-10-29 CN CN201380068925.3A patent/CN104884462A/zh active Pending
- 2013-10-29 EP EP13851564.8A patent/EP2912050A4/en not_active Withdrawn
- 2013-10-29 HK HK16102408.4A patent/HK1214270A1/zh unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2791523C1 (ru) * | 2022-12-08 | 2023-03-09 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-О-(3-фенилпропионил)-N4-гидроксицитидин и его применение |
| RU2791916C1 (ru) * | 2022-12-08 | 2023-03-14 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Способ получения 5'-О-(3-фенилпропионил)-N4-гидроксицитидина |
| WO2024123207A1 (ru) * | 2022-12-08 | 2024-06-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение |
| WO2024123206A1 (ru) * | 2022-12-08 | 2024-06-13 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина |
| RU2817201C1 (ru) * | 2023-10-18 | 2024-04-11 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-О-(4-фенилбутаноил)-N4- гидроксицитидин и его применение |
| RU2817609C1 (ru) * | 2023-10-18 | 2024-04-16 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 5'-О-(4-хлорфеноксиацетил)-N4-гидроксицитидин и его применение |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2889717A1 (en) | 2014-05-08 |
| HK1214270A1 (zh) | 2016-07-22 |
| JP2015535261A (ja) | 2015-12-10 |
| EP2912050A1 (en) | 2015-09-02 |
| KR20150090894A (ko) | 2015-08-06 |
| BR112015009636A2 (pt) | 2017-12-12 |
| EP2912050A4 (en) | 2016-09-28 |
| MX2015005500A (es) | 2016-02-09 |
| BR112015009636A8 (pt) | 2018-04-17 |
| WO2014070771A1 (en) | 2014-05-08 |
| US20140235566A1 (en) | 2014-08-21 |
| CN104884462A (zh) | 2015-09-02 |
| US9809616B2 (en) | 2017-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015119999A (ru) | Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака | |
| JP2015535261A5 (https=) | ||
| JP7703518B2 (ja) | 抗ウイルスプロドラッグ及びその製剤 | |
| RU2664534C2 (ru) | Пролекарственная форма тенофовира и ее фармацевтические применения | |
| RU2013125713A (ru) | Пуринмонофосфатные пролекарства для лечения вирусных инфекций | |
| EP0702556B1 (en) | (phospho)lipids for combatting hepatitis b virus infection | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| TWI642677B (zh) | 非環狀核苷膦酸二酯 | |
| EP0781138B1 (en) | Lipid analogs for treating viral infections | |
| AU2011239560B2 (en) | Phosphonates with reduced toxicity for treatment of viral infections | |
| CA2410579A1 (en) | Methods and compositions for treating flaviviruses and pestiviruses | |
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2011525171A5 (https=) | ||
| RU2007102281A (ru) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae | |
| DK1140745T3 (da) | Colchinolderivater som vaskulært skadelige midler | |
| JP2004533401A5 (https=) | ||
| CN103232490B (zh) | 具有抑制hiv-1/hbv病毒复制活性的核苷类化合物、制备方法及抗病毒方面的应用 | |
| RU2011106364A (ru) | Жидкие составы | |
| JPWO2022251502A5 (https=) | ||
| RU2015147555A (ru) | Соединения, модифицирующие теломеры посредством теломеразы | |
| JP2021501791A5 (https=) | ||
| US20020188011A1 (en) | Antiviral agents and methods of treating viral infections | |
| RU2017110512A (ru) | Противовирусные агенты и их применение | |
| ES2338642T3 (es) | Terapia de combinacion para tratar virus de la hepatitis b. | |
| CN110655546B (zh) | 索非布韦衍生物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180605 |